KR20240042009A - 항-cd38 항체, 항-cd3 항체, 및 이중특이적 항체 및 이의 용도. - Google Patents

항-cd38 항체, 항-cd3 항체, 및 이중특이적 항체 및 이의 용도. Download PDF

Info

Publication number
KR20240042009A
KR20240042009A KR1020247007197A KR20247007197A KR20240042009A KR 20240042009 A KR20240042009 A KR 20240042009A KR 1020247007197 A KR1020247007197 A KR 1020247007197A KR 20247007197 A KR20247007197 A KR 20247007197A KR 20240042009 A KR20240042009 A KR 20240042009A
Authority
KR
South Korea
Prior art keywords
seq
nos
antigen
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247007197A
Other languages
English (en)
Korean (ko)
Inventor
마크 치우
만-청 펑
마크 토네타
브라이언 휘태커
푸 푸
잉 진
첸 펭
케니스 청 퀑
아오 유
글렌 마크 앤더슨
Original Assignee
항저우 우노젠 바이오테크, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 항저우 우노젠 바이오테크, 리미티드 filed Critical 항저우 우노젠 바이오테크, 리미티드
Publication of KR20240042009A publication Critical patent/KR20240042009A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020247007197A 2021-08-02 2022-08-02 항-cd38 항체, 항-cd3 항체, 및 이중특이적 항체 및 이의 용도. Pending KR20240042009A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163228195P 2021-08-02 2021-08-02
US63/228,195 2021-08-02
PCT/US2022/074409 WO2023015170A2 (en) 2021-08-02 2022-08-02 Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Publications (1)

Publication Number Publication Date
KR20240042009A true KR20240042009A (ko) 2024-04-01

Family

ID=83049800

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247007197A Pending KR20240042009A (ko) 2021-08-02 2022-08-02 항-cd38 항체, 항-cd3 항체, 및 이중특이적 항체 및 이의 용도.

Country Status (9)

Country Link
US (1) US20250277051A1 (https=)
EP (1) EP4380977A2 (https=)
JP (1) JP2024528935A (https=)
KR (1) KR20240042009A (https=)
CN (1) CN117751144A (https=)
AU (1) AU2022323166A1 (https=)
CA (1) CA3226428A1 (https=)
IL (1) IL310024A (https=)
WO (1) WO2023015170A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途
WO2025162453A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体前药及其应用
WO2025201240A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2025201242A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
CN119236080A (zh) * 2024-09-29 2025-01-03 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种医药组合物在制备用于治疗多发性硬化药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
JP6775422B2 (ja) * 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA43219A (fr) * 2015-11-10 2018-09-19 Univ Medical Center Hamburg Eppendorf Polypeptides de liaison d'antigène dirigés contre cd38
CA3078800A1 (en) * 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
BR112021000173A2 (pt) * 2018-10-26 2021-05-04 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd38
CA3144961A1 (en) * 2019-07-01 2021-01-07 Sorrento Therapeutics, Inc. Heterodimeric antibodies that bind to cd38 and cd3

Also Published As

Publication number Publication date
WO2023015170A2 (en) 2023-02-09
JP2024528935A (ja) 2024-08-01
EP4380977A2 (en) 2024-06-12
US20250277051A1 (en) 2025-09-04
IL310024A (en) 2024-03-01
WO2023015170A3 (en) 2023-04-06
CN117751144A (zh) 2024-03-22
CA3226428A1 (en) 2023-02-09
AU2022323166A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
US20250270314A1 (en) Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
US11845795B2 (en) NKp46 binding proteins
EP3464367B1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US20250277051A1 (en) Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
JP2020109117A (ja) Ｂｃｍａに対するモノクローナル抗体
WO2015063187A1 (en) Multivalent antigen-binding proteins
HK1217958A1 (zh) 四价双特异性抗体
CN102958942A (zh) 异二聚体结合蛋白及其应用
CA3145387A1 (en) Fusion proteins comprising a ligand-receptor pair and a biologically functional protein
WO2020227457A1 (en) Materials and methods for modulating t cell mediated immunity
WO2015146437A1 (ja) 高機能性ＩｇＧ２型二重特異性抗体
WO2023051727A1 (zh) 结合cd3的抗体及其用途
JP2022504826A (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
WO2022081794A1 (en) Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
US20250230248A1 (en) Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
WO2024114676A1 (zh) Cldn18.2/4-1bb结合蛋白及其医药用途
CA3229824A1 (en) Methods of treating cancers associated with immunosuppressive b cells
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
KR20230079390A (ko) 감소된 응집 능력 및 감소된 소수성을 갖는 개선된 항-oxMlF 항체
JP7822466B2 (ja) 低減された凝集能及び低減された疎水性を有する、改善されたＦｃサイレンシングされた抗ｏｘＭＩＦ抗体
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2025201242A1 (en) Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
EP4585618A1 (en) Anti-ilt4 antibody and pharmaceutical use thereof
Vega et al. New antibody formats
Vukovic et al. In a therapeutic setting, mouse IgG2a isotype is superior to mIgG1 or mIgE in controlling tumor growth

Legal Events

Date Code Title Description
PA0105 International application
PG1501 Laying open of application